Aktis Oncology, Inc.

AKTSNASDAQHealthcare● Active

$18.97

+$0.10(+0.53%)

Market Cap$1.0B

P/E Ratio—

52W High$29.16

52W Low$14.72

Avg Volume322K

Open$19.00

Beta1.10

Overview

Aktis Oncology, Inc. (AKTS) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

AKTS · earnings · updated Jun 9, 2026

Latest Earnings

Q2 FY2026Report Date: May 11, 2026

EPS Actual

-$0.38

Est. -$0.31 · -22.6%

Revenue

$0.00B

Est. $0.00B · +67.2%

Fiscal Period

Q2 FY2026

FY ends December

Report Date

May 11, 2026

After Market Close

▼ Miss EPS▲ Beat Revenue

AKTS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

$93.32

Rev. $1001.5B

Days Away84

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.$93.32

Rev. Est.$1001.5B

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
◌ Q3 FY2026	Sep 2, 2026	-$0.42	—	—	—	$0.00B	—
◌ Q3 FY2026	Aug 10, 2026	-$0.42	—	—	—	$0.00B	—
◌ Q2 FY2026	Jun 3, 2026	-$0.33	—	—	—	$0.00B	—
▼ Q2 FY2026	May 11, 2026	-$0.31	-$0.38	-22.6%	$0.00B	$0.00B	+67.2%
▲ Q1 FY2026	Mar 30, 2026	-$21.59	-$18.19	+15.8%	$0.00B	$0.00B	-43.0%

Q3 FY2026

Sep 2, 2026

EPS Actual

—

EPS Est.

-$0.42

EPS Surpr.

—

Revenue

—

Q3 FY2026

Aug 10, 2026

EPS Actual

—

EPS Est.

-$0.42

EPS Surpr.

—

Revenue

—

Q2 FY2026

Jun 3, 2026

EPS Actual

—

EPS Est.

-$0.33

EPS Surpr.

—

Revenue

—

Q2 FY2026

May 11, 2026Miss

EPS Actual

-$0.38

EPS Est.

-$0.31

EPS Surpr.

-22.6%

Revenue

$0.00B

Q1 FY2026

Mar 30, 2026Beat

EPS Actual

-$18.19

EPS Est.

-$21.59

EPS Surpr.

+15.8%

Revenue

$0.00B

Analyst Estimates

Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.

EPS Estimates

Period	Low	Consensus	High	# Analysts
Q4 FY2028	$-1.62	$-0.93	$-0.57	3
Q3 FY2028	$-1.64	$-0.94	$-0.57	2
Q2 FY2028	$-1.56	$-0.89	$-0.54	2
Q1 FY2028	$-1.57	$-0.90	$-0.55	3
Q4 FY2027	$-1.26	$-0.72	$-0.44	2
Q3 FY2027	$-1.23	$-0.70	$-0.43	1

Revenue Estimates

Period	Low	Consensus	High	# Analysts
Q4 FY2028	$0.0B	$0.0B	$0.0B	1
Q3 FY2028	$0.0B	$0.0B	$0.0B	1
Q2 FY2028	$0.0B	$0.0B	$0.0B	1
Q1 FY2028	$0.0B	$0.0B	$0.0B	1
Q4 FY2027	$0.0B	$0.0B	$0.0B	1
Q3 FY2027	$0.0B	$0.0B	$0.0B	2

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
▼ Q2 FY2026	May 11, 2026	-22.6%	$18.60	$18.27	-1.77%
▲ Q1 FY2026	Mar 30, 2026	+15.8%	$15.19	$16.54	+8.89%

Q2 FY2026-1.77%

Report Date

May 11, 2026

EPS Beat/Miss

-22.6%

Price Before

$18.60

Price After

$18.27

Q1 FY2026+8.89%

Report Date

Mar 30, 2026

EPS Beat/Miss

+15.8%

Price Before

$15.19

Price After

$16.54

Avg Beat Reaction+8.89%

Avg Miss Reaction-1.77%

Beat Rate1 / 2 quarters

Largest Move+8.89% (Q1 FY2026)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Aktis Oncology, Inc. (AKTS) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.38 — missing the analyst consensus of $-0.31 by -22.6%. The next AKTS earnings date is expected around September 1, 2026.

Each quarter, investors track AKTS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AKTS revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

AKTS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

AKTS earnings · 5 questions

Aktis Oncology, Inc.'s next earnings report is expected around September 1, 2026. AKTS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AKTS historically reports after market close (AMC).

AKTS earnings datewhen is AKTS earningsAKTS next earnings datewhen does AKTS report earningsAKTS earnings calendar

▸ Source: FMP · Aktis Oncology, Inc. SEC filings · US GAAP · Aktis Oncology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026